- Home
- LMNR vs CELC Comparison
LMNR vs CELC Comparison
Compare LMNR & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMNR
- CELC
- Stock Information
- Founded
- LMNR 1893
- CELC 2011
- Country
- LMNR United States
- CELC United States
- Employees
- LMNR N/A
- CELC N/A
- Industry
- LMNR Farming/Seeds/Milling
- CELC Medical Specialities
- Sector
- LMNR Consumer Staples
- CELC Health Care
- Exchange
- LMNR Nasdaq
- CELC Nasdaq
- Market Cap
- LMNR 440.5M
- CELC 440.7M
- IPO Year
- LMNR N/A
- CELC 2017
- Fundamental
- Price
- LMNR $22.67
- CELC $13.15
- Analyst Decision
- LMNR Hold
- CELC Strong Buy
- Analyst Count
- LMNR 1
- CELC 6
- Target Price
- LMNR $25.00
- CELC $30.17
- AVG Volume (30 Days)
- LMNR 44.4K
- CELC 184.2K
- Earning Date
- LMNR 03-06-2025
- CELC 03-26-2025
- Dividend Yield
- LMNR 1.32%
- CELC N/A
- EPS Growth
- LMNR N/A
- CELC N/A
- EPS
- LMNR 0.40
- CELC N/A
- Revenue
- LMNR $191,503,000.00
- CELC N/A
- Revenue This Year
- LMNR $6.42
- CELC N/A
- Revenue Next Year
- LMNR $5.90
- CELC N/A
- P/E Ratio
- LMNR $56.68
- CELC N/A
- Revenue Growth
- LMNR 6.45
- CELC N/A
- 52 Week Low
- LMNR $17.49
- CELC $10.35
- 52 Week High
- LMNR $29.22
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- LMNR 42.45
- CELC 60.85
- Support Level
- LMNR $22.23
- CELC $12.55
- Resistance Level
- LMNR $23.50
- CELC $13.25
- Average True Range (ATR)
- LMNR 0.52
- CELC 0.68
- MACD
- LMNR 0.09
- CELC 0.14
- Stochastic Oscillator
- LMNR 39.86
- CELC 85.79
About LMNR Limoneira Co
Limoneira Co is an agribusiness company. The company's operating segments include Fresh Lemons; Lemon Packing; Avocados and Other Agribusiness. It generates maximum revenue from the Fresh Lemons segment.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.